Megan Dunbar

Megan Dunbar

Auto-generated profile, based on publicly available information

Megan Dunbar

Pangaea Zimbabwe AIDS Trust (PZAT), Harare, Zimbabwe

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2021 in AIDS and Behavior
Verified
Journal Article
Open access
PDF file
CMCollin Mangenah
Collin Mangenah
DNDefinate Nhamo
Definate Nhamo
SGStephano Gudukeya
Stephano Gudukeya
EGEmily Gwavava
Emily Gwavava
CGChiedza Gavi
Chiedza Gavi
FTFern Terris-Prestholt
Fern Terris-Prestholt
Although oral PrEP is highly effective at preventing HIV acquisition, optimizing continuation among beneficiaries is challenging in many settings. We estimated the costs of delivering oral PrEP to populations at risk of HIV in seven clinics in Zimbabwe. Full annual economic costs of oral PrEP initiations and continuation visits were estimated from the providers’ perspective for a six-clinic NGO network and one government SGBV clinic in Zimbabwe (January–December 2018). Disaggregating costs of full initiation and incremental follow-up visits enabled modeling of the impact of duration of continuation on the cost per person-year ($pPY) on PrEP. 4677 people initiated oral PrEP, averaging 2.7 follow-up visits per person. Average cost per person initiated was $238 ($183–$302 across the NGO clinics; $86 in the government facility). The full cost per initiation visit, including central and direct costs, was $178, and the incremental cost per follow-up visit, capturing only additional resources used directly in the follow up visits, was $22. The average duration of continuation was 3.0 months, generating an average $pPY of $943, ranging from $839 among adolescent girls and young women to $1219 in men. Oral PrEP delivery costs varied substantially by scale of initiations and by duration of continuation and type of clinic. Extending the average oral PrEP continuation from 2.7 to 5 visits (about 6 months) would greatly improve service efficiency, cutting the $pPY by more than half.

30 August 2025 in HIV Medicine
Verified
Journal Article
Open access
GPGerald Pierone
Gerald Pierone
LBLaurence Brunet
Laurence Brunet
JFJennifer S. Fusco
Jennifer S. Fusco
MSMichael G. Sension
Michael G. Sension
MDMegan S. Dunbar
Megan S. Dunbar
GFGregory P. Fusco
Gregory P. Fusco
Objectives: To compare the virologic effectiveness and discontinuation of the commonly prescribed fixed‐dose combination 3‐drug and 2‐drug regimens, bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) and dolutegravir/lamivudine (DTG/3TC), in virologically suppressed individuals in routine clinical care in the US. Methods: From the OPERA cohort, ART‐experienced, virologically suppressed (viral load <200 copies/mL) adults with HIV who switched to B/F/TAF or DTG/3TC (01AUG2020‐30JUN2022) were followed through 31DEC2022, death, loss to follow‐up or discontinuation. Cox proportional hazard models with stabilized inverse probability of treatment weights were used to assess the association between regimen and time to confirmed virologic failure (cVF 200 ; 2 viral loads ≥200 copies/mL or 1 viral load ≥200 copies/mL + discontinuation) or time to discontinuation. Results: A total of 3512 B/F/TAF users were followed for a median of 16 months (IQR: 11, 22); 2327 DTG/3TC users were followed for a median of 15 months (IQR: 10, 21). cVF 200 was observed among 2% of B/F/TAF and 3% of DTG/FTC users, for an adjusted hazard ratio of 0.84 (95% CI: 0.59, 1.18) for B/F/TAF compared with DTG/3TC. Regimen discontinuation was observed among 17% of B/F/TAF and 19% of DTG/3TC users, for an adjusted hazard ratio of 0.83 (95% CI: 0.73, 0.94) for B/F/TAF compared with DTG/3TC. Treatment‐related reasons for discontinuation represented 6% of B/F/TAF and 9% of DTG/3TC discontinuations. Conclusions: In this large US cohort, both B/F/TAF and DTG/3TC were well tolerated and effective treatment options among virologically suppressed individuals in routine clinical care, although DTG/3TC tended to be discontinued faster than B/F/TAF.

5 October 2021 in AIDS and Behavior
Verified
Journal Article
Closed access
PDF file
CMCollin Mangenah
Collin Mangenah
DNDefinate Nhamo
Definate Nhamo
SGStephano Gudukeya
Stephano Gudukeya
EGEmily Gwavava
Emily Gwavava
CGChiedza Gavi
Chiedza Gavi
FTFern Terris-Prestholt
Fern Terris-Prestholt